Frontiers in Genetics (Sep 2021)
Comprehensive Analysis of Splicing Factor and Alternative Splicing Event to Construct Subtype-Specific Prognosis-Predicting Models for Breast Cancer
- He Zhang,
- He Zhang,
- He Zhang,
- He Zhang,
- Baoai Han,
- Baoai Han,
- Baoai Han,
- Baoai Han,
- Xingxing Han,
- Xingxing Han,
- Xingxing Han,
- Xingxing Han,
- Yuying Zhu,
- Yuying Zhu,
- Yuying Zhu,
- Yuying Zhu,
- Hui Liu,
- Hui Liu,
- Hui Liu,
- Hui Liu,
- Zhiyong Wang,
- Zhiyong Wang,
- Zhiyong Wang,
- Zhiyong Wang,
- Yanfen Cui,
- Yanfen Cui,
- Yanfen Cui,
- Yanfen Cui,
- Ran Tian,
- Ran Tian,
- Ran Tian,
- Ran Tian,
- Zicong Gao,
- Zicong Gao,
- Zicong Gao,
- Zicong Gao,
- Ruinan Tian,
- Ruinan Tian,
- Ruinan Tian,
- Ruinan Tian,
- Sixin Ren,
- Sixin Ren,
- Sixin Ren,
- Sixin Ren,
- Xiaoyan Zuo,
- Xiaoyan Zuo,
- Xiaoyan Zuo,
- Xiaoyan Zuo,
- Jianfei Tian,
- Jianfei Tian,
- Jianfei Tian,
- Jianfei Tian,
- Fei Zhang,
- Fei Zhang,
- Fei Zhang,
- Fei Zhang,
- Ruifang Niu,
- Ruifang Niu,
- Ruifang Niu,
- Ruifang Niu
Affiliations
- He Zhang
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- He Zhang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- He Zhang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- He Zhang
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Baoai Han
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Baoai Han
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Baoai Han
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Baoai Han
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Xingxing Han
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xingxing Han
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Xingxing Han
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Xingxing Han
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Yuying Zhu
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Yuying Zhu
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Yuying Zhu
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Yuying Zhu
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Hui Liu
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Hui Liu
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Hui Liu
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Hui Liu
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Zhiyong Wang
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Zhiyong Wang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Zhiyong Wang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Zhiyong Wang
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Yanfen Cui
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Yanfen Cui
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Yanfen Cui
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Yanfen Cui
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Ran Tian
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Ran Tian
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Ran Tian
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Ran Tian
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Zicong Gao
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Zicong Gao
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Zicong Gao
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Zicong Gao
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Ruinan Tian
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Ruinan Tian
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Ruinan Tian
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Ruinan Tian
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Sixin Ren
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Sixin Ren
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Sixin Ren
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Sixin Ren
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Xiaoyan Zuo
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiaoyan Zuo
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Xiaoyan Zuo
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Xiaoyan Zuo
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Jianfei Tian
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Jianfei Tian
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Jianfei Tian
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Jianfei Tian
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Fei Zhang
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Fei Zhang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Fei Zhang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Fei Zhang
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- Ruifang Niu
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Ruifang Niu
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Ruifang Niu
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Ruifang Niu
- Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin, China
- DOI
- https://doi.org/10.3389/fgene.2021.736423
- Journal volume & issue
-
Vol. 12
Abstract
Recent evidence suggests that splicing factors (SFs) and alternative splicing (AS) play important roles in cancer progression. We constructed four SF-risk-models using 12 survival-related SFs. In Luminal-A, Luminal-B, Her-2, and Basal-Like BRCA, SF-risk-models for three genes (PAXBP1, NKAP, and NCBP2), four genes (RBM15B, PNN, ACIN1, and SRSF8), three genes (LSM3, SNRNP200, and SNU13), and three genes (SRPK3, PUF60, and PNN) were constructed. These models have a promising prognosis-predicting power. The co-expression and protein-protein interaction analysis suggest that the 12 SFs are highly functional-connected. Pathway analysis and gene set enrichment analysis suggests that the functional role of the selected 12 SFs is highly context-dependent among different BRCA subtypes. We further constructed four AS-risk-models with good prognosis predicting ability in four BRCA subtypes by integrating the four SF-risk-models and 21 survival-related AS-events. This study proposed that SFs and ASs were potential multidimensional biomarkers for the diagnosis, prognosis, and treatment of BRCA.
Keywords